Details About Generic Salt ::  Estropip

Main Medicine Class:: Estrogen   

(ESS-troe-PIH-pate)
Ogen, Ortho-Est
Class: Estrogen

 

Drugs Class ::

 Action Promotes growth and development of female reproductive system and secondary sex characteristics; affects release of ovulation and prevents postpartum breast engorgement; conserves calcium and phosphorous and encourages bone formation; overrides stimulatory effects of testosterone.

Indications for Drugs ::

 Indications Management of moderate to severe vasomotor symptoms associated with menopause; female hypogonadism, female castration, primary ovarian failure and atrophic conditions caused by deficient endogenous estrogen production; prevention and treatment of osteoporosis.

Drug Dose ::

 Route/Dosage

Vasomotor Symptoms

ADULTS: PO 0.625 to 5 mg/day given cyclically.

Female Hypogonadism, Female Castration, Primary Ovarian Failure

ADULTS: PO 1.25 to 7.5 mg/day for 3 wk followed by 8 to 10 day drug-free period.

Osteoporosis

ADULTS: PO 0.625 mg/day for 25 days of 31-day cycle.

Atrophic Vaginitis, Kraurosis Vulvae

ADULTS: PO 0.625 to 5 mg/day. Give cyclically. Intravaginal 2 to 4 g daily. Give cyclically.

Contraindication ::

 Contraindications Breast cancer; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; thrombophlebitis or thromboembolic disorders associated with previous estrogen use; known or suspected pregnancy.

Drug Precautions ::

 Precautions

Pregnancy: Category X. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Calcium and phosphorus metabolism: Use drug with caution in patients with metabolic bone diseases. Fluid retention: Use drug with careful observation when conditions that might be affected by this factor are present (eg, asthma, cardiac or renal dysfunction, epilepsy). Gallbladder disease: Risk of gallbladder disease may increase in women receiving postmenopausal estrogens. Hepatic function impairment: Metabolism may be impaired; use drug with caution. Induction of malignant neoplasms: May increase risk of endometrial or other carcinomas. Familial hyperlipoproteinemia: May be associated with massive elevations of plasma triglycerides. Uterine leiomyomata: Preexisting uterine leiomyomata may increase in size. Unopposed estrogen administration (eg, without progesterone): Increases risk of uterine cancer. Therefore, when using estrogens on long-term basis in a woman with intact uterus, consider cyclic therapy with progesterone (eg, estrogen on days 1 to 25 of mo with progesterone added for last 12 days) or daily coadministration of estrogen plus progesterone on daily basis. In a woman without uterus, use of cyclic therapy and/or therapy with progesterone is not necessary.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CV: Thrombosis; thrombophlebitis; increased BP; pulmonary embolism; MI. CNS: Headache; migraine; dizziness; depression; insomnia; anxiety; emotional lability. DERM: Chloasma; melasma; erythema nodosum/multiforme; scalp hair loss; hirsutism; urticaria; dermatitis; skin hypertrophy; pruritus. EENT: Intolerance to contact lenses. GI: Nausea; vomiting; abdominal cramps; bloating; colitis; acute pancreatitis; diarrhea; dyspepsia; flatulence; gastritis; gastroenteritis; enlarged abdomen; hemorrhoids. GU: Increased risk of endometrial carcinoma; breakthrough bleeding; dysmenorrhea; amenorrhea; vaginal candidiasis; premenstrual-like syndrome; increased size of uterine fibromyomata; hemolytic uremic syndrome; urinary tract infection; vaginitis; vaginal discomfort/pain; cystitis; dysuria; genital pruritus; urinary incontinence. HEPA: Cholestatic jaundice. META: Hyperglycemia; hypercalcemia. RESP: Upper respiratory tract infection; sinusitis; rhinitis; pharyngitis; flu-like symptoms; allergy; bronchitis; chest pain. OTHER: Increase or decrease in weight; edema; changes in libido; breast tenderness; acute intermittent porphyria; vaginal bleeding; hypersensitivity reactions; back pain; arthritis; arthralgia; hot flushes; otitis media; toothache.

Drug Mode of Action ::  

 Action Promotes growth and development of female reproductive system and secondary sex characteristics; affects release of ovulation and prevents postpartum breast engorgement; conserves calcium and phosphorous and encourages bone formation; overrides stimulatory effects of testosterone.

Drug Interactions ::

 Interactions

Antidepressants, tricyclic: Estrogens may alter effects and increase toxicity of these agents. Barbiturates, rifampin: May decrease estropipate concentration. Corticosteroids: An increase in the pharmacologic and toxicologic effects of corticosteroids may occur. Hydantoins: Loss of seizure control or decreased estrogenic effects may occur.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Include in physical assessments BP measurements, and examination of breasts, abdomen and pelvic organs. Review results of Pap test, which should be conducted at least annually.
  • Monitor blood sugar in diabetic patients and report changes to health care provider.
  • Be alert for changes in liver function test results and possible decreased PT.
OVERDOSAGE: SIGNS & SYMPTOMS
  Nausea, withdrawal bleeding in women

Drug Storage/Management ::

 Administration/Storage

  • Administer vaginal cream high in vagina (about  length of applicator).
  • Give tablets with meal to decrease GI upset.

Drug Notes ::

 Patient/Family Education

  • Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use reliable form of birth control while taking this drug.
  • Instruct patient to report these symptoms to physician: pain in groin or calves; sharp chest pain or sudden shortness of breath; abnormal vaginal bleeding; breast lumps; sudden severe headache; dizziness or fainting; vision or speech problems; weakness or numbness of arms or legs; severe abdominal pain; yellowing of skin or eyes; or severe depression.
  • Advise patient to stop smoking or to reduce number of cigarettes smoked to < 15/day because of increased risk of cardiovascular complications.
  • Remind patient to have Pap smear every 6–12 mo while undergoing therapy.
  • Teach patient proper method of breast self-examination.
  • Advise patient to avoid prolonged exposure to sunlight or other sources of UV light. Sunscreens and protective clothing should be used until tolerance is determined.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

DOWNLOAD OUR ANDROID APP

One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.